Forecast Insight: Inflammatory Bowel Disease - New product launches sustain long-term market growth
The inflammatory bowel disease market is set to grow from $2.9 billion in 2008 to $4.5 billion in 2018 across the seven major markets. While Datamonitor's updated forecast will parallel its previous forecast up to 2012, several new product launches, regional expansion and upgraded brand forecast will help to sustain growth in the second half of the forecast period. ( http://www.bharatbook.com/Market-Research-Reports/Forecast-Insight-Inflammatory-Bowel-Disease-New-product-launches-sustain-long-term-market-growth.html )
Scope of this research
Analysis of the current and future market dynamics in inflammatory bowel disease across the US, France, Germany, Italy, Spain the UK and Japan
Assessment of over 25 key marketed inflammatory bowel disease brands and late stage pipeline products
Snapshot of inflammatory bowel disease drug sales outside the seven major markets
Insight through key opinion leader comments to support conclusions
Research and analysis highlights
Several events, such as new product launches and regional expansion, will ensure sustained sales growth in the latter part of the forecast period, overcoming biosimilar entry. Datamonitor's updated forecast shows sales in the seven major markets will reach $4.5 billion in 2018.
SONIC trial data shows a u-turn in previous opinion on beginning anti-TNF in combination with immunosuppressant therapy in biologic- or immunosuppressant-naïve Crohn's disease patients. Datamonitor expects any impact from SONIC on clinical practice to emerge slowly within the next 2 years, and will impact across the TNF class.
Cimzia (certolizumab) is better able to compete with Abbott's Humira (adalimumab) in Crohn's disease with its new pre-filled syringe formulation. Cimzia's monthly dosing schedule together with its pre-filled syringe and lower cost will enable the drug to capture almost a quarter of the US anti-TNF market, in terms of sales, in 2018.
Key reasons to purchase this research
Understand how new brands Lialda and Apriso will fare against established market players, such as Asacol and Pentasa
Assess the impact of the launch of Cimzia's recent pre-filled syringe and gauge future dynamics within the anti-TNF class
Quantify the current and future size of the inflammatory bowel disease market
To know more and to buy a copy of your report feel free to visit : ( http://www.bharatbook.com/Market-Research-Reports/Forecast-Insight-Inflammatory-Bowel-Disease-New-product-launches-sustain-long-term-market-growth.html )
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com |
